Ingalls & Snyder LLC Buys 961 Shares of Novo Nordisk A/S (NYSE:NVO)

Ingalls & Snyder LLC boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 1.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 52,646 shares of the company’s stock after buying an additional 961 shares during the quarter. Ingalls & Snyder LLC’s holdings in Novo Nordisk A/S were worth $4,529,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of NVO. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S in the third quarter worth approximately $28,000. Capital Performance Advisors LLP bought a new stake in Novo Nordisk A/S during the third quarter worth $42,000. Albion Financial Group UT boosted its position in Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock worth $44,000 after purchasing an additional 278 shares during the last quarter. Sound Income Strategies LLC boosted its position in Novo Nordisk A/S by 82.1% in the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock worth $46,000 after purchasing an additional 243 shares during the last quarter. Finally, Hager Investment Management Services LLC purchased a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $46,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on NVO shares. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. StockNews.com lowered Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $145.25.

Novo Nordisk A/S Trading Down 2.3 %

Shares of NVO stock opened at $81.78 on Thursday. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.75. The business has a 50-day moving average of $90.45 and a 200 day moving average of $110.60. The stock has a market capitalization of $366.99 billion, a PE ratio of 24.86, a P/E/G ratio of 0.96 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.86 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st will be paid a $0.7874 dividend. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date is Monday, March 31st. Novo Nordisk A/S’s dividend payout ratio (DPR) is 21.88%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.